Protagenic Therapeutics Stock Price To Earning
| PTIX Stock | USD 0.65 0.04 6.56% |
Protagenic Therapeutics fundamentals help investors to digest information that contributes to Protagenic Therapeutics' financial success or failures. It also enables traders to predict the movement of Protagenic Stock. The fundamental analysis module provides a way to measure Protagenic Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Protagenic Therapeutics stock.
Protagenic |
Protagenic Therapeutics Company Price To Earning Analysis
Protagenic Therapeutics' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Protagenic Therapeutics Price To Earning | 9.43 X |
Most of Protagenic Therapeutics' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Protagenic Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, Protagenic Therapeutics has a Price To Earning of 9.43 times. This is 63.51% lower than that of the Biotechnology sector and 91.28% higher than that of the Health Care industry. The price to earning for all United States stocks is 67.17% higher than that of the company.
Protagenic Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Protagenic Therapeutics' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Protagenic Therapeutics could also be used in its relative valuation, which is a method of valuing Protagenic Therapeutics by comparing valuation metrics of similar companies.Protagenic Therapeutics is currently under evaluation in price to earning category among its peers.
Protagenic Fundamentals
| Return On Equity | -2.06 | ||||
| Return On Asset | -0.9 | ||||
| Current Valuation | (721.57 K) | ||||
| Shares Outstanding | 6.79 M | ||||
| Shares Owned By Insiders | 14.24 % | ||||
| Shares Owned By Institutions | 5.76 % | ||||
| Number Of Shares Shorted | 89.12 K | ||||
| Price To Earning | 9.43 X | ||||
| Price To Book | 5.75 X | ||||
| EBITDA | (4.5 M) | ||||
| Net Income | (5 M) | ||||
| Cash And Equivalents | 8.87 M | ||||
| Cash Per Share | 0.51 X | ||||
| Total Debt | 655.25 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 19.47 X | ||||
| Book Value Per Share | 0.83 X | ||||
| Cash Flow From Operations | (3.7 M) | ||||
| Short Ratio | 1.33 X | ||||
| Earnings Per Share | (1.27) X | ||||
| Target Price | 4.0 | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 4.04 M | ||||
| Total Asset | 4.32 M | ||||
| Retained Earnings | (30.78 M) | ||||
| Working Capital | 3.54 M | ||||
| Current Asset | 3.75 M | ||||
| Current Liabilities | 736 K | ||||
| Net Asset | 4.32 M |
About Protagenic Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Protagenic Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protagenic Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protagenic Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.